NEW YORK (GenomeWeb) – PDI said after the close of the market Wednesday that its Interpace Diagnostics subsidiary will enter the molecular diagnostics market through the acquisition of two microRNA-based from Asuragen.

PDI said that it will pay Asuragen $8 million upfront in cash, future commercial milestone-based payments, and royalties for the miRInform Thyroid and Pancreas cancer tests, IP related to the tests and other tests in development for thyroid cancer, as well as a tissue sample biobank containing more than 5,000 samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.